IRCT20200105046010N109招募中Unknown
Bioequivalence study of eltrombopag 50 mg tablet manufactured by Nanodaru Co versus originator brand (Revolade 50 mg) manufactured by Novartis Co. in fasting condition in healthy volunteers
anodaru Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to eltrombopag
研究者
相似试验
已完成
1 期
Bioequivalence Study of 25 mg Eltrombopag Film-coated Tablets in Healthy Thai VolunteersBioequivalence Study of 25 mg Eltrombopag Film-coated Tablets in Healthy Thai VolunteersTCTR20221107003nison Laboratories Co., Ltd.48
招募中
Unknown
Bioequivalence study of empagliflozin 10 mg tabletIn the present study, no disease was investigated..IRCT20230222057495N3Yab Daro Company24
已完成
Unknown
Bioequivalence study of Empagliflozin ?? mg.IRCT20220111053692N18Tehran Chemie Pharmaceutical Company24
招募中
Unknown
Bioequivalence study of Empagliflozin 25 mg tabletIRCT20200105046010N83kharazmi company24
尚未招募
不适用
Bioequivalence study of Empagliflozin 12.5 mg+ Metformin 1000 mg in 24 healthy male under fasting conditionsIRCT20180620040164N13ACtover Pharmaceutical Co26